Rapport Therapeutics, Inc. (RAPP) Form 424B5 — Oct 27, 2026
Rapport Therapeutics (Nasdaq: RAPP) launched a follow-on common stock offering priced off a preliminary prospectus supplement dated October 27, 2026, with the last reported sale price at $25.33 per share on October 26, 2026. Morgan Stanley, Leerink Partners and Evercore ISI are acting as representatives of the underwriters. The equity offering is paired with a concurrent convertible senior notes offering (notes due December 1, 2032) and a concurrent private placement to a single investor at the public offering price, with a 6.0% placement agent fee on the private placement. None of the three transactions is contingent on the others.
Key figures
- Total Debt
- 0
- Total Assets
- 0
- Cash Position
- 436077000
- Shares Outstanding
- 47955079
- Atm shelf available
- 150000000
- Stock options outstanding
- 8030456
- Convertible notes maturity
- December 1, 2032
- Net tangible book value total
- 422500000
- Net tangible book value per share
- 8.81
- Weighted avg option exercise price
- 16.43
- Last reported sale price 2026 10 26
- 25.33
- Placement agent fee private placement pct
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.